2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - La Nouvelle A-B
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Deep Learning, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

936 Longitudinal single-cell Lineage–State mapping reveals the clonal origins and heritable states of therapy persistence in multiple myeloma

Teng Gao, Chen Weng, Ph.D2, Isaac Johnson3, Michael Poeschla4, Jonas Gudera5, Emily King6, Christopher Rouya7, Adriana Donovan8, Lauren Bourke9, Ying Shao10, Eladio Marquez11, Rahul Tyagi12, Leonard I Zon13, Jonathan S. Weissman14, Vijay G Sankaran, MD, PhD15
1 Boston Children's Hospital, Boston, United States
2 Boston Children's Hospital, Boston, United States
3 Boston Children's Hospital, Boston, United States
4 Boston Children's Hospital, Boston, United States
5 Boston Children's Hospital, Boston, United States
6 Boston Children's Hospital, Boston, Massachusetts, United States
7 Boston Children's Hospital, Boston, Massachusetts, United States
8 Branch Biosciences, Cambridge, United States
9 Branch Biosciences, Cambridge, United States
10 Branch Biosciences, Cambridge, United States
11 Branch Biosciences, Cambridge, United States
12 Branch Biosciences, Cambridge, United States
13 Boston Children's Hospital, Boston, United States
14 Whitehead Intitute, Cambridge, Massachusetts, United States
15 Boston Children's Hospital, Boston, Massachusetts, United States, Boston Children's Hospital, Boston, Massachusetts, United States

Background: Multiple myeloma (MM) nearly always relapses after an initial response. Linking the longitudinal lineage histories of tumor cells to their molecular states is essential for determining whether residual disease arises through selection of pre-existing lineages with stable resistance programs or through reversible state transitions across multiple lineages. However, most single-cell studies capture molecular state without lineage history, while copy-number alterations (CNAs) resolve only major tumor subclones and cannot distinguish ancestry within copy-number-identical populations. We therefore sought to establish a longitudinal lineage-state framework to identify the clonal origins and molecular states associated with post-treatment persistence.

Methods: ReDeeM is an experimental platform that simultaneously profiles RNA, chromatin accessibility, and somatic mitochondrial DNA (mtDNA) mutations at high depth in the same single cells. Because somatic mtDNA mutations are inherited by daughter cells, shared mutation patterns serve as endogenous barcodes for reconstructing lineage relationships, while the matched RNA and chromatin measurements define each cell’s molecular state. We applied ReDeeM to paired bone marrow samples collected at diagnosis and after 6–8 cycles of cyclophosphamide, bortezomib, and dexamethasone induction therapy from three patients with MM (ages 70–82 years; two male and one female), profiling 20,311 malignant plasma cells. We developed MitoDrift, a population-genetic lineage-inference method that models mtDNA heteroplasmy drift and single-cell sampling noise to quantify branch confidence and generate confidence-refined lineage trees. MitoDrift was independently benchmarked against lentiviral barcode-defined lineages in primary human hematopoietic stem and progenitor cells. In MM, the inferred phylogenies were integrated with RNA/ATAC-defined cell states, CNA subclones, and phylogeny-based analyses of state coupling, transition, and heritability. Clinical relevance was evaluated in 68 patients with paired diagnosis and relapse samples from the MMRF CoMMpass cohort.

Results: Against independent lineage ground truth, confidence-refined MitoDrift trees recovered 75% of barcode-defined clones at 77% clade precision (Jaccard similarity ≥0.5), outperforming Neighbor-Joining (55% precision) and UPGMA (28% precision). In MM, mtDNA phylogenies captured major CNA-defined lineages (Moran’s I=0.41–0.76) while resolving additional intraclonal structure. Within a therapy-resistant 1q-gain subclone, MitoDrift identified subclades with distinct pre- versus post-treatment distributions. It also detected therapy-associated clonal remodeling in two patients without detectable CNA subclones. In the deepest responder, clonal diversity increased after therapy (mtDNA Shannon diversity index, 2.3 to 4.3), indicating elimination of dominant clones and persistence of a polyclonal reservoir rather than selection of a single resistant clone. Longitudinal phylogeny-state analysis showed that pre-treatment dormant/signaling-dampened and adaptive signaling/stress-buffered states were most closely related to post-treatment cells and had the highest heritability (Moran’s I=0.28 and 0.23, respectively). In contrast, proliferative and progenitor-like states were largely plastic (Moran’s I=0.02 for both). Within the 1q-gain subclone, a CD44-positive adhesion/migratory state had the shortest phylogenetic distance to post-treatment cells. Consistent with this association, higher CD44 expression at relapse predicted inferior overall survival in CoMMpass (hazard ratio=3.37, P=0.0034).

Conclusions: Longitudinal integration of lineage history and cell state resolves therapy-associated clonal evolution beyond CNA-defined subclones and distinguishes stable lineage-associated resistance programs from plastic tumor states. In a deep responder, persistent MM arose from multiple lineages rather than a single resistant clone. These analyses nominate CD44-associated adhesion programs as candidate mediators of treatment resistance and establish a framework for identifying the clonal origins and molecular states that drive post-treatment persistence.

Chen Weng, Ph.D: No relevant conflicts of interest to declare.